Market Close Report, 4 September 2026: Sensex, Nifty Close Flat as IT Drags

Today at a glance

Today, 4 September 2026: Sensex closed at 76,515.43, down 54.97 points (-0.07%), marking a flat session. IT and healthcare stocks led the decline as profit-taking capped weekly momentum. SBILIFE was the top gainer; HCLTECH the top loser. For SIP investors, quiet consolidation days provide a steady environment to continue systematic investments without emotional distraction.

What happened in the markets today

On Friday, 4 September 2026, the Sensex today closed at 76,515.43, slipping 54.97 points (-0.07%), while the Nifty 50 settled at 23,897.70, down 16.70 points (-0.07%). The broader market witnessed rangebound trading as strong gains in life insurers and Reliance Industries offset weakness across software exporters and pharmaceutical manufacturers. In commodities and currency, Gold softened to $4,516 (-0.53%), Silver settled at $67.47 (-0.35%), Crude Oil fell to $90.75 (-0.60%), and the USD/INR currency pair traded flat at 94.48 (+0.01%). Why did Nifty fall today? Nifty consolidated and edged slightly lower as weakness in IT and pharma stocks offset gains in life insurers and metal heavyweights.

Movers: Insurance gain, Technology drag Nifty

Life insurance providers and metal manufacturers drew steady investor demand, helping buffer the broader market against sharper declines. Conversely, technology exporters and pharmaceutical companies faced mild profit-taking ahead of the weekend.

In the news

• Rupee Rises 2 Paise Against U.S. Dollar — The Indian rupee appreciated marginally by two paise to settle at 94.49 against the greenback on Friday, supported by easing crude oil benchmarks and mild dollar sales from domestic banks. While foreign portfolio flows remained subdued throughout the trading session, lower import bills from softer commodity prices provided immediate currency relief. The Reserve Bank of India continues to monitor cross-border capital flows closely to curb sudden currency swings. For domestic mutual fund investors, a stable domestic currency preserves foreign purchasing power and anchors imported inflation expectations. [Source: The Hindu]
• The Ayurveda Co Shuts Operations Following Rapid Expansion — Direct-to-consumer wellness enterprise The Ayurveda Co announced the total closure of its commercial operations after scaling to a peak valuation of ₹250 crore. Founders attributed the sudden shutdown to aggressive retail store expansion that strained liquidity amid rising customer acquisition costs across digital channels. The development highlights increasing structural pressure across venture-funded consumer retail brands facing fierce competition from entrenched legacy players. Equity analysts noted that disciplined unit economics and sustainable working capital management remain vital across emerging consumer business models. [Source: The Hindu]
• Cipla Inks Partnership With Qilu Pharma for Cancer Biosimilar — Leading pharmaceutical firm Cipla finalized an exclusive strategic collaboration with China-based Qilu Pharma to commercialize a crucial cancer biosimilar across specified international markets. The pact grants Cipla licensed rights to distribute the oncology asset, enhancing its specialized therapeutic portfolio in oncology care. This development underscores Indian pharma majors expanding pipeline breadth through targeted cross-border technical alliances rather than solely proprietary research outlays. Industry watchers view the partnership as an efficient approach to securing regulatory approvals and meeting critical therapeutic needs globally. [Source: The Hindu]
• Italy Regulator Clears Tata Motors Unit Offer for Iveco — Financial authorities in Italy formally cleared an offer submitted by an overseas subsidiary of Tata Motors to acquire common equity shares in commercial vehicle manufacturer Iveco. The regulatory approval clears a primary compliance obstacle for the commercial automotive conglomerate as it broadens its European industrial manufacturing presence. Acquiring an established stake allows Tata Motors to deepen engineering synergies and integrate alternative-fuel commercial vehicle platforms across continental European routes. Market observers regard the move as a long-term strategic step toward expanding international commercial vehicle footprint. [Source: The Hindu]
• Cohance Lifesciences Commits $18 Million to Targeted ADC Platforms — Integrated healthcare contract development company Cohance Lifesciences announced an $18 million equity investment across NJ Bio and Aruka Bio to bolster antibody-drug conjugate capabilities. The capital injection seeks to accelerate high-potency payload synthesis and specialized bioconjugation manufacturing services for global biotech innovators. As demand for targeted oncology therapeutics escalates worldwide, specialized contract manufacturers with advanced antibody capabilities stand to capture high-margin development contracts. The investment signals growing domestic corporate participation in high-value biopharmaceutical manufacturing chains. [Source: The Hindu]

What it means for SIP investors

Quiet trading sessions where benchmark indices finish virtually unchanged often tempt investors to second-guess their portfolio strategies. However, sideways market periods represent natural consolidation phases within multi-year market cycles. When indices trade flat, disciplined rupee cost averaging quietly works in your favor by eliminating the impulse to time daily market fluctuations.

Rather than reacting to day-to-day headlines or short-term sector rotations, long-term investors achieve superior compounding by adhering to a predefined allocation. If you ever feel tempted to pause contributions when markets stall, reviewing should you continue SIP during market crash reinforces why emotional reactions impair compounding. For those building a balanced foundation, following our framework on how to build mutual fund portfolio from scratch helps ensure your capital remains diversified across resilient asset classes.

Returns snapshot — 1-day & long-term

Despite modest daily fluctuations, Indian equity benchmarks maintain healthy structural valuations near their historic highs, reflecting ongoing domestic economic resilience.